Echosens and Novo Nordisk A/S announced a partnership to advance the early diagnosis of NASH and increase awareness of the disease. They have collaborated to support additional clinical validation, the generation of real-world evidence, and the adoption of non-invasive diagnostic tests for NASH. They decided to collaborate for raising awareness of the condition and the value of early diagnosis and treatment. By 2025, the companies hope to double the rate of advanced-stage to severe NASH diagnoses.
GENFIT company announced the launch of the NASHnext, a novel, non-invasive diagnostic test for nonalcoholic steatohepatitis (NASH). The test is offered exclusively in the U.S. and Canada through Labcorp, a leading global life sciences company. NASHnext, GENFIT's proprietary diagnostic technology, is powered by NIS4 and was described in The Lancet Gastroenterology and Hepatology as using a novel blood-based molecular biomarker test to detect NASH and significant fibrosis, also known as at-risk NASH, in patients with at least one metabolic risk factor.
Author Credits: Radhika Gupta, Shivam Bhutani